Podcasts about ii iii

This week, Pastor Rebecca shared some hard lessons she's learned about finances: sometimes, you don't know what you don't know until you find out. Preaching on scripture from the Book of Acts, her sermon explains that God is always trying to reveal to you, again and again, what more is possible.

2019年高考全国II+III卷英语听力第一节 (共5小题；每小题1.5分，满分7.5分)听下面5段对话。每段对话后有一个小题，从题中所给的A、B、C三个选项中选出最佳选项。听完每段对话后，你都有10秒钟的时间来回答有关小题和阅读下一小题。每段对话仅读一遍。1.Where does the conversation probably take place? A. In a library. B. In a bookstore. C. In a classroom.2.How does the woman feel now? A. Relaxed. B. Excited. C. Tired.3.How much will the man pay? A. $520. B. $80. C. $100.4.What does the man tell Jane to do? A. Postpone his appointment. B. Meet Mr. Douglas. C. Return at 3 o'clock.5.Why would David quit his job? A. To go back to school. B. To start his own firm. C. To work for his friend.第二节 (共15小题，每小题1.5分，满分22.5分)听下面5段对话或独白。每段对话或独白后有几个小题，从题中所给的A、B、C三个选项中选出最佳选项。听每段对话或独白前，你将有时间阅读各个小题，每小题5秒钟；听完后，各小题将给出5秒钟的作答时间。每段对话或独白读两遍。听第6段材料，回答第6、7题。6.What does the man want the woman to do? A. Check the cupboard. B. Clean the balcony. C. Buy an umbrella.7.What is the probable relationship between the speakers? A. Husband and wife. B. Employer and employee. C. Shop assistant and customer.听第7段材料，回答第8至10题。8.Where did the woman go at the weekend? A. The city centre. B. The forest park. C. The man's home.9.How did the man spend his weekend? A. Packing for a move. B. Going out with Jenny. C. Looking for a new house.10.What will the woman do for the man? A. Take Henry to hospital. B. Stay with his kid. C. Look after his pet. 听第8段材料，回答第11至13题。11.What is Mr. Stone doing now? A. Eating lunch. B. Having a meeting. C. Writing a diary.12.Why does the man want to see Mr. Stone? A. To discuss a program. B. To make a travel plan. C. To ask for sick leave.13.When will the man meet Mr. Stone this afternoon? A. At 3:00. B. At 3:30. C. At 3:45.听第9段材料，回答第14至16题。14.What are the speakers talking about? A. A company. B. An interview. C. A job offer.15.Who is Monica Stansfield? A. A junior specialist. B. A department manager. C. A sales assistant.16.When will the man hear from the woman? A. On Tuesday. B. On Wednesday. C. On Thursday.听第10段材料，回答第17至20题。17.What did John enjoy doing in his childhood? A. Touring France. B. Playing outdoors. C. Painting pictures.18.What did John do after he moved to the US? A. He did business. B. He studied biology. C. He worked on a farm.19.Why did John go hunting? A. For food. B. For pleasure. C. For money.20.What is the subject of John's works? A. American birds. B. Natural scenery. C. Family life.参考答案1—5BCBAC 6—10 CABAC11—15 BACCB 16—20 ACABA录音原文(Text1)W: Excuse me, how can I find the book called The Class of 1998.M: Oh, I'm afraid it was sold out.W: It's all right. Thank you.(Text2)M:How did your dancing lesson go today?W: Exciting, but it was hard work. I really need a rest now.M: Yeah, I can see that. Go and get relaxed.(Text3)M:How much is that in total?W: One hundred dollars. But ifyou have a membership card, I can give you a 20% discount. M: Great! This is my membership card.(Text4)M: Jane, I'm going out for awhile. W: But you have an appointment with Mr. Douglas at 3 o'clock.M: Well, please make it another day.(Text5)W: David said he would quit his job at our school.M: Really? Why would he do that?W: His friend started a firm in London. She wanted David to help her.(Text6)W: I'm going out for shopping. Do you need anything? M: Oh yeah, I can't find my umbrella. Can you buy one?W: Shouldn't it be in the cupboard?M: I just checked. It wasn't there.W: Impossible! That was where I usually put it. Did you check the balcony?M: Yes, of course. Couldn't find it. Well, just get a new one then.(Text7)M: Hi, Lucy. How was your weekend?W: Great! You know, we went mountain-climbing in the forest park. The air was so different from the city.Cool and fresh.M: Sounds great.W: Yeah. There wasn't a cloud in the sky and we could see for miles from the top. What about you? What did you do?M: Busy packing.W: Oh, yes, of course! I forgot you and Jenny are moving into a new house. It's on Wednesday, isn't it?M: Yeah, two days after. I didn't realize there are so many things to do.W: Can I help out with anything?M: Emm, it'd be nice if you could take care of Henry for a couple of days.W: Henry?M: Yes, my dog.W: Oh, sure. No problem. You just focus on the move.(Text8)M: Hello, can I speak to Mr.Stone, please?W: Hello, but I'm afraid Mr.Stone is in a meeting until lunchtime. Can I take a message?M: Well, yes. I'd like to make an appointment to see him. It's Harrison White here.W: Just a second, Mr. White. I'll look in the diary. So, when's convenient for you?M: Sometime today if possible. I hear he'll be away tomorrow.W: Yes, that's right. He'll be on a business trip for a week.M: I need to talk about my new program with him before he leaves. It's urgent. So would this afternoon be okay?W: Let me see... OK, Mr. Stone is free this afternoon, after 3:00.M: Well, three o'clock is a bit difficult. But I could make it after 3:30.W: So shall we say a quarter to four this afternoon in Mr. Stone's office?M: That's great. Thanks.(Text9)W: Hello.M: Hi, Cindy. This is Jake Lee at Fixit Corporation. How are you today?W: Oh, hi, Jake. I'm fine. How are you?M: Good. The reason I'm calling is that we'd like to offer you the position you were interviewed for last Thursday.W: Oh, that's great. I was really impressed with Fixit.M: I'm glad to hear it. And we're prepared to offer you a starting salary of $55,000.W: I see. And vacation time?M: Oh, you get one day per month in your first year. That is, you'll have twelve days in your first year, and then increase if you stay longer with the company.W: What would be my job title?M: You'd be a junior specialist and you'd be working under Monica Stansfield, the department manager.W: OK... Is the salary negotiable at all?M: Well, this is typical for new staff.W: I see.M: Why don't you think about it?I'll need to hear back from you by Wednesday. Will that work?W: Sure, no problem. I'll let you know Tuesday afternoon.(Text10)M: Hello, everybody! Today, I'd like to share with you something about John Audubon. John was born on April 26,1785. He spent much of his childhood in France where he spent many hours each day outdoors painting pictures. At the age of 18, he moved to the United States. Well,actually, John began his life in the US as a businessman. However, instead of taking care of his business, John was often off exploring nature. At first,John spent his time hunting for fun. Then he found that the animals around were very beautiful and he particularly enjoyed observing the birds he saw. He began studying them, trying to learn the differences between the birds, and noticing their different behaviors. Therefore, he painted the birds he observed a lot. In 1819, John realized that he didn't have enough money to pay his bills. He was very upset that he couldn't earn enough money to support his family, so he spent time improving his painting skills and began to sell his paintings. He discovered that he could earn some money while doing something he really enjoyed. We are lucky now to have so many paintings of American birds by John Audubon.

2018年全国高考II+III卷英语听力第一节 (共5小题；每小题1.5分，满分7.5分)听下面5段对话。每段对话后有一个小题，从题中所给的A、B、C三个选项中选出最佳选项。听完每段对话后，你都有10秒钟的时间来回答有关小题和阅读下一小题。每段对话仅读一遍。1.What does John find difficult in learning German? A. Pronunciation. B. Vocabulary. C. Grammar.2.What is the probable relationship between the speakers? A. Colleagues. B. Brother and sister. C. Teacher and student.3.Where does the conversation probably take place? A. In a bank. B. At a ticket office. C. On a train.4.What are the speakers talking about? A. A restaurant. B. A street. C. A dish.5.What does the woman think of her interview? A. It was tough. B. It was interesting. C. It was successful.第二节 (共15小题，每小题1.5分，满分22.5分)听下面5段对话或独白。每段对话或独白后有几个小题，从题中所给的A、B、C三个选项中选出最佳选项。听每段对话或独白前，你将有时间阅读各个小题，每小题5秒钟；听完后，各小题将给出5秒钟的作答时间。每段对话或独白读两遍。听第6段材料，回答第6、7题。6.When will Judy go to a party? A. On Monday. B. On Tuesday. C. On Wednesday.7.What will Max do next? A. Fly a kite. B. Read a magazine. C. Do his homework.听第7段材料，回答第8、9题。8.What does the man suggest doing at first? A. Going to a concert. B. Watching a movie. C. Playing a computer game.9.What do the speakers decide to do? A. Visit Mike. B. Go boating. C. Take a walk.听第8段材料，回答第10至12题。10.Which color do cats see better than humans? A. Red. B. Green. C. Blue.11.Why do cats bring dead birds home? A. To eat them in a safe place. B. To show off their hunting skills. C. To make their owners happy.12.How does the man sound at the end of the conversation? A. Grateful. B. Humorous. C. Curious.听第9段材料，回答第13至16题。13.Who is Macy? A. Ed's mother. B. Ed's teacher. C. Ed's friend.14.How does Ed usually go to kindergarten? A. By car. B. On foot. C. By bus.15.What does Ed enjoy doing at the kindergarten? A. Telling stories. B.Singing songs. C. Playing with others.16.What do the teachers say about Ed? A. He's clever. B. He's quiet. C. He's brave.听第10段材料，回答第17至20题。17.At what age did Emily start learning ballet? A. Five. B. Six. C. Nine.18.Why did Emily move to Toronto? A. To work for a dance school. B. To perform at a dance theater. C. To learn contemporary dance.19.Why did Emily quit dancing? A. She was too old to dance. B. She failed to get a scholarship. C. She lost interest in it.20.How does Emily feel about stopping training? A. She's pleased. B. She's regretful. C. She's upset.参考答案1—5CABAC 6—10 BBACC11—15ABABC 16—20 ABCCA录音原文(Text1)W: So how is your German classgoing, John?M: Well, not bad. Thepronunciation is fine with me and its vocabulary is similar to English. But I'mfinding the grammar awful.W: Well, it takes a while to getit right.(Text2) W: I hope you can come to theparty on Saturday.M: I didn't know I was invited.W: Sure you are! Everyone in ouroffice is invited.(Text3)W: May I help you?M: Yes, when is the next train toLondon?W: Oh, let me check. It leaves intwenty minutes.M: One ticket, please.(Text4)W: Charlie, do you know arestaurant called Bravo?M: Bravo… I know the name. ButI'm not sure where it is.W: It's on George Street. Thefood there is excellent.(Text5)W: Brian, I just had aninterview. They said they would make a decision soon.M: What are your chances ofgetting the job?W: Quite good. I think theinterview went very well.(Text6)M: Let's go kite-flying, Judy.It's such a lovely day.W: OK. But let me finish mychemistry homework first. Would you mind waiting for half an hour, Max? Thereare a few sports magazines on the table. M: Isn't the chemistry homeworkdue next Wednesday?W: Yeah. But I have a full day ofclasses on Monday and a birthday party to attend on Tuesday.M: All right then, you go ahead.And I'll catch up on some sports news while waiting.(Text7)W: We've been on the computer allthe time lately. Why don't we do something different Sunday afternoon?M: Well, we could go to aconcert...W: But I don't think we can getthe tickets this late.M: Then, what about playing acomputer game? There's a really cool new one we could download.W: Hmm. I don't know. I feel likeI need to do some exercise. We could probably just walk by the lake, and I'llask Mike to join us.M: That sounds like fun. Let's doit!(Text8)W: Welcome to our program, Dr.Peterson. Let's see what questions we've got for you today. Here's one: Cancats see color?M: Sort of. In the wild, manycats hunt at night because their eyes are designed for low light. Your catcan't see bright colors, such as red and green, but it picks up more shades ofblue, yellow, and gray than humans do.W: And why do cats “give” deadbirds to their owners?M: When your cat drops a deadbird at your feet, she isn't bringing you a present. Most cats just drag foodhome because it's a safe place to eat. A cat's mom also brings home things toher children to help them practice hunting. So a female cat without childrenmay bring these “treats” to her owner instead. You may not like them, but atleast, you don't have to write her a thank-you note.(Text9)W: How is little Ed doing at thekindergarten, Jack?M: Oh, he's doing fairly well.It's been three weeks since he first started going, so Macy and I are prettyused to it now. You should have seen Macy cry when Ed was about to set off onthe first day, though!W: I think that's a normalreaction for mothers. You live quite close to the kindergarten, don't you? Howdoes he get there?M: Macy walks there with himevery morning, unless the weather is bad. When it rains, they'll drive.W: And is Ed enjoyingkindergarten?M: Yeah, he loves to have otherkids to play with. He keeps telling us things they do together.W: What do the teachers at thekindergarten say about him?M: They said he is bright andthat he's starting to learn how to tell time. Isn't that fantastic?W: That is fantastic. It soundslike everything goes well.(Text10)W: My name is Emily. I had been adancer for quite a long time—I started studying ballet when I was six yearsold. By the time I was nine, I was dancing five days a week. When I waseighteen, I decided that I really preferred contemporary dance and that I wantedto do it professionally. So, I applied successfully for the training program atthe School of Toronto Dance Theater and moved to Toronto to attend the program.That was the period of time I enjoyed most in Toronto. I graduated onscholarship and danced professionally for ten years, but after all those years,I found that dance was gradually becoming something that felt like more of aburden than a joy; I found myself increasingly unwilling to drag myself todance performances, so I quit. I do miss dance often, but it makes me happy tothink that I'll never have to go to another training session again.

2017年全国高考II+III卷英语听力第一节（共5小题，每小题1.5分，满分7.5分）听下面5段对话，每段对话后有一个小题，从题中所给的A、B、C三个选项中选出最佳答案。听完每段对话后，你都有10秒钟的时间来回答有关小题和阅读下一小题。每段对话仅读一遍。1．What will the woman do this afternoon?A．Do some exercise.　　 B．Go shopping. C．Wash her clothes. 2．Why does the woman call the man?A．To cancel a flight. B．To make an apology. C． To put off a meeting. 3．How much more does David need for the car?A．$ 5,000. B．$20,000. C．$25,000.4．What is Jane doing?A．Planning a tour. B．Calling her father. C．Asking for leave.5．How does the man feel?A．Tied. B．Dizzy. C．Thirsty. 第二节（共15小题；每小题1.5分，满分22.5分）听下面5段对话或独白。每段对话或独白后有几个小题，从题中所给的A、B、C三个选项中选出最佳选项。听每段对话或独白前，你将有时间阅读各个小题，每小题5秒钟；听完后，各小题将给出5秒钟的作答时间。每段对话或独白读两遍。听第6段材料，回答第6、7题。6. What does Jack want to do?A. Watch TV. B. Play outside. C. Go to the zoo.7. Where does the conversation probably take place?A. At home. B. In a cinema. C. In a supermarket.听第7段材料，回答第8至10题。8. What does Richard do? A. He's a newsman. B. He's a manager. C. He's a researcher.9. Where is Richard going next week? A. Birmingham. B. Mexico City. C. Shanghai.10. What will the speakers do tomorrow? A. Eat out together. B. Visit a university. C. See Professor Hayes.听第8段材料，回答第11至13题。11. What is the probable relationship between the speakers?A. School friends.B. Teacher and student.C. Librarian and library user.12. Why does Jim suggest Mary buy the book?A. It's sold at a discount price.B. It's important for her study.C. It's written by Professor Lee.13. What will Jim do for Mary?A. Share his book with her.B. Lend her some money.C. Ask Henry for help.听第9段材料，回答第14至16题。14.Where does Stella live? A. In Memphis. B. In Boston. C. In St Louis.15.What would Peter and his family like to do on Beale Street? A. Visit a museum. B. Listen to music C. Have dinner.16.What kind of hotel does Peter prefer? A big one. B. A quite one. C.A modern one.听第10段材料，回答第17至20题。17.How many lab sessions will the students have every week?A. One. B. Two. C. Three.18.What are the students allowed to wear in the lab ? A. Long scarves. B. Loose clothes. C. Tennis shoes.19.Why should the students avoid mixing liquid with paper? A. It may cause a fire. B. It may create waste. C. It may produce pollution.20.What does the speaker mainly talk about?A. Grades the student will receive.B. Rules the students should follow.C. Experiments the students will do. 参考答案1—5 BCACB 6—10 ACCBA 11—15 ABCAB 16—20 BACAB2017年全国新课标卷II+III英语听力原文Text 1M: Let's go for a nice walk into the country this afternoon.W: I certainly could enjoy the exercise, but I've agreed to go with Alice to buy some clothes. Text 2W: Hello, Mr. Smith. I'm afraid Dr. Brown won't be able to see you today. He's still waiting for a flight out of New York. He said he would meet you tomorrow afternoon. Is it OK?M: Sounds good. Thank you for calling. Text 3W: David, have you saved enough for the car?M: I have $20,000 now, and the car costs $25,000. My parents said they would like to help, but I don't want to use their money. Text 4W: Dr. Block, I need to take a few days off because my father is coming over to visit. And I need to show him around the city.M: OK, Jane. But be sure to come back to work next week. Text 5M: Amy, my head is spinning! It must be a touch of the sun.W: You'd better lie back still for a while. Take it easy for the rest of the day, and stay in the shade. It's too hot today. Text 6M: Mom, this is going to take forever! Animal World will be on in 20 minutes. It's my favorite program. You know I can't miss it!W: I know, honey. But we have to wait in line to pay for these things we need.M: You promised we'd be home in time.W: Be a little patient, Jack. We'll get out of here soon.Text 7M: Hi, Samantha. Do you have a minute?W: Hi, Richard. Come in, please.M: I've been trying to get hold of you all afternoon.W: I was at the weekly managers' meeting. How are things?M: Oh, splendid. I have some news.W: Good news?M: Wonderful news…to me, anyway! I've been offered a job for three years as an assistant to Prof. Hayes from Birmingham University. I'll join him in Mexico City. What do you think about that?W: Wonderful, Richard! Just what you've always wanted, isn't it? Does it mean that you'll leave soon?M: Next week. But before I go, I'd like to invite you out for dinner — just to thank you for all the help you gave me during my three-month research work here. Would tomorrow evening be a good time for you? We can go to the Shanghai Restaurant in Chinatown.W: Fine with me. Text 8M: What's that book you just picked up, Mary?W: The one Prof. Lee uses in his course.M: Oh, I see. You'd better have it if you want to pass that course.W: But it costs $30. I simply can't afford it.M: Did you check the used book section here? Maybe they have it.W: No, they don't. I asked.M: Why don't you get it from the library?W: I've been trying for months, and it's always out. There are over 50 students in the course, and every single one wants the book.M: Listen, you know my roommate Henry, don't you? He took the same course last year, and I remember he owns a copy. I can borrow it from him for you.W: Oh, that'll be great! Thank you, Jim!text 9W: Hello?M: Hello, Stella. This is Peter.W: Hi, Peter. Fancy hearing your voice! How are you?M: Couldn't be better. I'm planning a trip to Memphis with my family this summer.W: Great! I'd love to host you here. When are you coming?M: We'll leave Boston on June 20th, stay in St. Louis, Missouri for a week, and then fly to your city. We'd probably stay for five days with you and come back, for it's a two-week vacation.W: Is there anything special you'd like to do here?M: We'd love to explore Beale Street, the official home of the blues, where we'd listen to live music. We'd also like to visit Graceland, the popular museum in memory of Elvis Presley. But above all, we want to spend some time with you and your family.W: Of course! It's been ages since we met last time. Let's have a dinner party in my garden.M: Lovely! Oh, could you find for us a hotel near where you live? It doesn't have to be big, but I can't stand noise at bedtime.W: Sure.M: Thank you. See you soon. Text 10M: Hello, everyone. My name is John. I'm the teaching assistant for this lab session. Let me explain a little about it. As you may know already, it's a required meeting once a week. I expect you to do all the experiments and keep the results in your lab notebook. I'll collect the notebooks every two weeks. You'll be graded on lab notebooks and quizzes. But the most important information I want to give you now is about safety. First of all, you must wear shoes that cover your feet in the lab. Tennis shoes are OK. Also, don't wear loose clothes, long scarves, big necklaces, or loose belts — they get caught in something or fall into liquid. Another thing to do for safety is cleaning up. Be sure to put the waste in the correct containers. We can't mix liquid with paper. This is extremely important. I don't want any fires in this room. You are responsible for washing out your own lab equipment and putting it away. If you don't do this, I will take away points from your grade. Nobody's going to clean up after you. OK, any questions?

Featuring an interview with Dr Natalie Vokes, including the following topics: Perioperative minimal residual disease (MRD) detected by circulating tumor DNA (ctDNA) testing in patients with lung cancer (0:00) Ohara S et al. Clinical significance of perioperative MRD detected by ctDNA in patients with lung cancer with a long follow-up data: An exploratory study. JTO Clin Res Rep 2024;6(3):100762. Abstract Masuda K et al. MRDSEEKER (JCOG2111A): A prospective study to evaluate MRD and its association with prognosis in curative-intent NSCLC. World Conference on Lung Cancer 2025;Abstract P3.18.04.  Zhou C et al. IMpower010: Biomarkers of disease-free survival in a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO IO 2021;Abstract 2O. MRD analysis of adjuvant therapy with osimertinib for resected EGFR-mutated Stage IB to IIIA non-small cell lung cancer (NSCLC) (8:28) Herbst RS et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med 2025;31(6):1958-68. Abstract MRD analyses of perioperative chemoimmunotherapy for resected NSCLC (15:12) Forde PM et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med 2025;393(8):741-52. Abstract  ctDNA dynamics in advanced NSCLC treated with immunotherapy (20:56) Vokes NI et al. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo). ASCO 2023;Abstract 9022. Anagnostou V et al. ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results. Nat Med 2023;29(10):2559-69. Abstract Anagnostou V et al. A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). ASCO 2025;Abstract TPS8669. CME information and select publications

El Dr. Saúl Campos Gómez, oncólogo médico del Centro Oncológico Estatal ISSEMyM, en Toluca, Estado de México, participa en el Taller de Residentes de Oncología Médica RISE, 8.ª edición, donde aborda el cáncer de pulmón de células no pequeñas en estadios II–III resecables y su manejo en adyuvancia.Fecha de grabación: 16 de enero de 2026.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos, para uso personal, y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.El contenido, las opiniones y declaraciones presentadas son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.ScienceLink y los terceros mencionados no se responsabilizan por daños o consecuencias derivados del uso, interpretación o aplicación de la información, ni por errores u omisiones.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

We listen to Nobuo Uematsu's overworld music from Final Fantasy 1, 2, & 3. We compare the 8-bit chiptunes to full orchestrations and even vocal renditions and hear similarities to Joe Hisaishi and Studio Ghibli music.JACK WHITE - IT MIGHT GET LOUD - INTRO (HD)The Girl Who Fell from the Sky - Castle in the skyDeath Shall Me DevourFinal Fantasy Pray The Promised Land FFII Main ThemeNausicaä - Nausicaä of the Valley of the Wind - Opening (01)FFXIV OST Crystal Tower Ending BGM / FF3 Map Theme ( Eternal Wind )Final Fantasy Pray Voyage FFIII The Boundless Ocean

Muhamad II-III. De como en los comienzos del Reino Nazari estos dos monarcas consolidaron el poder.

Wondering what collagen supplements actually do? We break down types I, II, III, and more—and dive deep into the latest research on skin, joints, hair, and muscle benefits.For more information about this topic: https://brianyeungnd.com/2025/07/31/the-real-benefits-of-collagen/Get EXCLUSIVE content and SUPPORT us: https://ko-fi.com/brianyeungndTop recommended supplement choices:Collagen (BioCell) - https://amzn.to/3Oz0knE - 1 to 2 caps / dayCollagen (fish) - https://amzn.to/3PFpz9t - 1 to 2 scoops / dayCollagen (Type 2) - https://amzn.to/3L6EcjF - 1 cap / day

An analysis of 35,000 stage II–III colon cancer cases shows relapse risk peaks in year one and falls below 0.5% per six-month interval by year six, offering a practical definition of cure and a basis to taper long-term follow-up. A second study estimates U.S. inhaler use generates over two million metric tons of annual emissions, with propellant-free devices offering lower-impact alternatives. Finally, lifestyle cohorts reveal about one-quarter of people with prediabetes can normalize glucose without weight loss, conferring >70% risk reduction over a decade and spotlighting fat distribution as a modifiable target.

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! PARTE 2 de 3 Continuamos con nuestro ciclo STAR WARS. Esta vez, como ya habíamos prometido, os traemos un especial de larga duración en el que tocaremos los Episodios I, II y III. Os garantizamos que el trío de la muerte compuesto por Raúl Martin, Nathan Kurtz y Antonio Runa desbrozará hasta el más ínfimo detalle cada una de estas tres producciones, objetivamente y con el mayor rigor, ofreciendo no sólo opinión (que también habrá, y mucha), sino muchos datos. Muchísimos datos. Más de lo que os imagináis. El ejercicio de examen y análisis de este programa va más allá de lo que puedas encontrar en cualquier otro programa dedicado a estas materias. Así que, si quieres saberlo todo, absolutamente todo y mucho más sobre LA AMENAZA FANTASMA, EL ATAQUE DE LOS CLONES y LA VENGANZA DE LOS SITH, no tienes más remedio que escuchar estas más de 4 horas de contenido sonoro. Os garantizamos que no os defraudará. Quizá sí lo haga el Gafapastas Eleuterio Minamorales, con su intervención radiofónica, pero para eso está. Después escucharemos las opiniones del oyente, un tributo a una plataforma de divulgación que se despide para siempre y un concurso donde regalaremos un pack muy especial. Si pudiéramos ofreceros más, lo haríamos, pero es imposible, así que a escuchar. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! PARTE 1 de 3 Continuamos con nuestro ciclo STAR WARS. Esta vez, como ya habíamos prometido, os traemos un especial de larga duración en el que tocaremos los Episodios I, II y III. Os garantizamos que el trío de la muerte compuesto por Raúl Martin, Nathan Kurtz y Antonio Runa desbrozará hasta el más ínfimo detalle cada una de estas tres producciones, objetivamente y con el mayor rigor, ofreciendo no sólo opinión (que también habrá, y mucha), sino muchos datos. Muchísimos datos. Más de lo que os imagináis. El ejercicio de examen y análisis de este programa va más allá de lo que puedas encontrar en cualquier otro programa dedicado a estas materias. Así que, si quieres saberlo todo, absolutamente todo y mucho más sobre LA AMENAZA FANTASMA, EL ATAQUE DE LOS CLONES y LA VENGANZA DE LOS SITH, no tienes más remedio que escuchar estas más de 4 horas de contenido sonoro. Os garantizamos que no os defraudará. Quizá sí lo haga el Gafapastas Eleuterio Minamorales, con su intervención radiofónica, pero para eso está. Después escucharemos las opiniones del oyente, un tributo a una plataforma de divulgación que se despide para siempre y un concurso donde regalaremos un pack muy especial. Si pudiéramos ofreceros más, lo haríamos, pero es imposible, así que a escuchar. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! PARTE 3 de 3 Continuamos con nuestro ciclo STAR WARS. Esta vez, como ya habíamos prometido, os traemos un especial de larga duración en el que tocaremos los Episodios I, II y III. Os garantizamos que el trío de la muerte compuesto por Raúl Martin, Nathan Kurtz y Antonio Runa desbrozará hasta el más ínfimo detalle cada una de estas tres producciones, objetivamente y con el mayor rigor, ofreciendo no sólo opinión (que también habrá, y mucha), sino muchos datos. Muchísimos datos. Más de lo que os imagináis. El ejercicio de examen y análisis de este programa va más allá de lo que puedas encontrar en cualquier otro programa dedicado a estas materias. Así que, si quieres saberlo todo, absolutamente todo y mucho más sobre LA AMENAZA FANTASMA, EL ATAQUE DE LOS CLONES y LA VENGANZA DE LOS SITH, no tienes más remedio que escuchar estas más de 4 horas de contenido sonoro. Os garantizamos que no os defraudará. Quizá sí lo haga el Gafapastas Eleuterio Minamorales, con su intervención radiofónica, pero para eso está. Después escucharemos las opiniones del oyente, un tributo a una plataforma de divulgación que se despide para siempre y un concurso donde regalaremos un pack muy especial. Si pudiéramos ofreceros más, lo haríamos, pero es imposible, así que a escuchar. Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

This week on The OncoAlert Weekly Round Up, we spotlight precision oncology in action with top-tier studies making headlines:

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The FDA has recently released over 200 complete response letters (CRLs) as part of its initiative to enhance transparency regarding the reasons behind the rejection of new drug and biologics applications. This effort reflects the agency's commitment to being more open with the public about its decision-making processes.In other news, AbbVie has made a significant acquisition by purchasing Ichnos Glenmark's lead myeloma antibody for nearly $2 billion, including a substantial upfront payment of $700 million. However, Ultragenyx and Mereo Biopharma faced challenges as their stocks declined following the announcement that the phase II/III study of their osteogenesis imperfecta candidate did not yield strong results during an interim analysis.Furthermore, there is growing concern surrounding the potential dismissal of the U.S. Preventive Services Task Force, following a Supreme Court ruling that affirmed Health Secretary Robert F. Kennedy Jr.'s authority to remove its members at his discretion. This development has raised questions about the future of preventive health initiatives in the country.For drug developers, finding the right balance between speed and quality is essential for achieving success in the industry. To optimize processes and leverage technology throughout the development journey, new digitization strategies are being explored. Embracing these advancements can help streamline operations and enhance overall efficiency in drug development efforts.

Episode recorded on July 10, 2025. Uwe Boll & Gary Otto host. Go to www.bollfilms.com

This podcast is the audio version of the Gear Garage Live Show, where we answer submitted questions and talk all things whitewater. Topics and links that Zach talked about in this episode The Perfect Paddling Fleece Answer Questions Grand Canyon Flip Video Some of the Questions that Zach covered in the Q&A section of this episode Topic: New Middle Fork My husband Harry is organizing a Middle Fork trip that puts in July 11. He has some questions about how the rapids in the upper section have changed since he last ran it in 2021. He was looking at your write-up on Whitewater Guidebook from 2023: Can you provide more info about the current situation? Topic: Dynamic rescue situations and rash decisions On a recent trip (all rafts w/ gear) we had a rower flip in the last wave of a rapid. There was a very short stretch of slack water before the next rapid. The next boat through was running tight and yelled out for the swimmer to swim to them. They very quickly got to her and pulled her from the water. The rower of the second boat then jumped out of his boat leaving the rescued swimmer to take his oars. He climbed onto the upside down boat, flipped it back over and climbed back on. It took him precious time to get the oars situated and be able to row through the next rapid, but literally came within seconds of going sideways over a nasty pour over at the very top of the rapid. Topic: Reducing Strainer Hazards on Flooding Rivers I live along a small continuous class II/III river in SW Colorado. Recently, runoff and flood waters have made the river fun and deep enough to run. River-wide strainers are a part of the process. Throughout the years a few of us in the local boating community have worked to remove them or inform people of their locations. We generally approach strainers of different types on a case-by-case basis. Normally we cut manageable chunks of wood out and remove them from the river as well as the branches. We let the unsafe and unmanageable pieces go and hope it floats away (four-foot pieces). Topic: R2 on the North Yuba We ran two r2 boats on North Fork Yuba from Goodyear bar on the Maytag run on June 3rd, 2025. The lead boat got surfed, and we were a bit close. We pursued the swimmer. I had a question about whether we should attempt to bump our friend out of the hydraulic or try to miss him. We hit his boat, but it didn't help him much, and we almost lost our line. I thought you would have some idea about this. Usually, we would grab an Eddie and try to get a line, but a swimmer was running downstream, and we decided we better pursue him first. Love your show and enjoy the weekly work you do to promote safety in white water rafting, Topic: Main Salmon River Hello Zach, I have been a big fan of your video trip reports for a long time now and I have noticed you have not made any videos on the Main Salmon River from Corn Creek to Carey Creek. Is there a certain reason for this ? I would love to know thanks Topic: Places to Raft What are the top 5 states to go rafting in the U.S. and also top places in South America, Europe and Asia?

Editor's choice: A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG Oncology/GOG studyEditorial: Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equityHosted by:Sean Dowdy, MD, FACS, FACOG, Associate Editor of Gynecologic OncologyFeaturing:V.L. Bae-Jump, University of North Carolina at Chapel Hill, Chapel Hill, NC, USABrian M. Slomovitz, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mount Sinai Medical Center, Miami Beach, FLCheck out more content on the journal's homepage  at https://www.gynecologiconcology-online.net

The Filtered Fragments (OG Filtrate)Joel TopfJennie LinSwapnil HiremathSpecial Guest Brad Rovin GN God and second author from The Ohio StateKoyal Jain GN Specialist from UNCAlfred Kim Rheumatologist from Washington UniversityEditing bySimon Topf and Nayan AroraThe Kidney Connection written and performed by by Tim YauShow NotesJoel's monologue One of the most surprising facts of nephrology is that despite conventional wisdom that lupus nephritis is an antibody mediated disease, that over a decade ago, the LUNAR investigtors were unable to find a significant benefit when rituximab was added to conventional therapy. And this was after the equally negative phase 2 trial of rituximab, EXPLORER.In fact, despite this finding rituximab has been able to burough its way into treatment of many nephrologists and rheumatologists as well as the KDIGO guidelines where it is suggested for patients with persistent disease activity or inadequate response to initial standard-of-care therapy.This long conflict is now coming to an end. Obinutuzumab, a newer, better monoclonal antibody targeting the same CD20 that we grew to love with rituximab, but it has a number of advantages.One. It is humanized antibody rather than a chimeric mouse-human antibodyTwo. It's cytotoxicity is not complement dependent an particular advantage if you want to deploy it ina disease where hypocomplementemia is a disease characteristicThree, and most importantly, it causes stronger and deeper b-cell depletion than rituximab. Better B-cell depletion in the blood and tissue.And this brings us to tonight's topic, we had already seen the phase two results of obinutuzumab which, unlike EXPLORER, were positive, we will look at the phase three regency trial. This makes the third novel lupus nephritis drug in the last 4 years. We continue to remake glomerular nephritis.LUNAR: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study PubmedEXPLORER: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial PubmedREGENCY: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis NEJM | NephJCNOBILITY: B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial Annals of Rheumatic DiseaseComparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program PubMed CentralClass 5 lupus nephritis is slow to respond Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study ACR Meeting abstractTubular SecretionsSwap: Young Adult novel I Must Betray You by Ruta Sepetys (Amazon)Koyal: Taekwondo (Wikipedia)Jennie: these unprecedented times Trump NYT: Administration Freezes $1 Billion for Cornell and $790 Million for Northwestern, Officials SayAl: Acquired PodcastBrad: The Feather Thief by Kirk Wallace Johnson (Amazon)Joel: Paradise on Hulu (Wikipedia)

Nesse artigo, Freud resume suas ideias principais ao afirmar que os sonhos são realizações disfarçadas de desejos inconscientes. Ele diferencia o conteúdo manifesto (o que lembramos) do conteúdo latente (seus verdadeiros significados), explicando como o trabalho do sonho transforma desejos ocultos em imagens oníricas por meio de mecanismos como condensação e deslocamento.Esse artigo se encontra no volume 5 das Obras Completas de Freud da Companhia das Letras, na tradução de Paulo César de Souza.

Far-right Russian thinker Aleksandr Dugin just sat down with Glenn Greenwald for an extensive interview, and we can't look away. Deep State Kuba joins Ben Burgis to watch some of it and discuss. Before that, Ben does an Opening Argument on the issues raised by the outrageous assault on free speech at Columbia. At the end of the main show, we play some of Daniel Tutt's guest appearance on Ben Burgis's Sunday afternoon Zoom Capital class to talk about the lumpenproletariat and tease Richard Wolff's guest lecture next Sunday. (Anyone who wants can join the class at patreon.com/benburgis and get instant access to all 25 class recordings so far, and of course join live for the approximately one trillion Sundays we've got left in the class (eight more chapters left in Vol. I, plus the entirety of Vols. II + III). Last but very far from least, in the postgame for patrons Ben and the crew chat with Yuri Rashkin, who actually did a Russian-language debate with Dugin a couple of years ago. Ben is accused of spreading "Kremlin propaganda" but somehow everyone parts as friends.Buy tickets for Ben's live show with Jason Myles on April 17th in San Francisco:https://www.universe.com/events/is-trump-the-end-of-history-tickets-J30WT9Follow Kuba on Twitter: @DrKuba2Follow Daniel on Twitter: @DanielTuttFollow Ben on Twitter: @BenBurgisFollow GTAA on Twitter: @Gtaa_ShowBecome a GTAA Patron and receive numerous benefits ranging from patron-exclusive postgames every Monday night to our undying love and gratitude for helping us keep this thing going:patreon.com/benburgisRead the weekly philosophy Substack:benburgis.substack.com

Join us this week for our massive breakdown of all the latest Bungie livestream info, going over the new activity; Court of Blades and the rest of the Act 2 & 3 details for Episode Heresy. We detail all the latest changes with the upcoming Guardian Games event coming this Tuesday at reset, including the new boss-rush mode Rushdown. We chat about the welcome improvements to the Trials of Osiris and Comp game modes. Respawn gets all emotional about the Sundered Doctrine Dungeon weapons and Monster Hunter for the 5 minutes we let him. Plus we have a few tips and tricks to help.   00:00:00 – Opening & Monster Hunter Chat 00:03:56 - More Monster Hunter Ramblings 00:04:49 - Introductions 00:06:03 - Moments of Triumph 2024 00:08:10 - Vault Space 00:17:51 - Trials of Osiris & Redrix's Estoc 00:31:08 - 14th Dregen Title Reset & Sundered Shenanigans 00:43:48 - Barrow-Dyad & Other Exotic Submachine Guns 00:50:24 - Moments Again 00:52:54 - Exo Body, Yes Please 00:54:03 - Heresy Act 2 Livestream Breakdown 01:01:02 - Dungeon Weapon Diversion 01:08:12 - Heresy Act 2 Weapon Breakdown 01:29:38 - Artifact Update & This Week at Bungie: March 6th 2025 01:29:38 - Heresy Act 3 Preview 01:40:53 - Rite Of The Nine Information 01:44:45 - Rite Of The Nine Weapons 01:52:57 - Guardian Games 2025 Information 01:55:25 - Guardian Games Weighting Issues In The Past 01:59:17 - Rushdown - New Boss Rush Mode 02:00:58 - Guardian Games Weapons 02:01:58 - Guardian Games Warning 02:03:17 - Guardian Games Glows 02:08:12 - Guardian Games Eververse 02:10:24 - Guardian Games Skimmer 02:12:05 - Guardian Games Cards & Rewards 02:15:09 - Guardian Games Rushdown Roulette 02:18:33 - Heresy Act 2 Crucible Update 02:28:06 - Trials This Week & Account Update 02:31:15 - Bungie Store Sale 02:32:30 - More Fashion Feedback 02:33:21 - Daylight Savings 02:34:18 - Account Recovery & Cheating 02:35:55 - Peroty's Player Support 02:43:34 - End Of The TWAB 02:44:38 - This Week In Destiny: Heresy Act 2 - Week 6 02:55:56 - Respawn Report Round-Up 02:59:49 - Tips, Tricks & Guides & Builds 03:08:16 - Patreon Thanks & End of the Show 03:11:47 - End Two Titans and a Hunter YouTube Channel Two Titans and a Hunter Twitch Two Titans and a Hunter Discord Two Titans and a Hunter - Patreon Two Titans and a Hunter Ko-Fi The100 io – GH/GD/2TAAH Group Email: twotitansandahunter@hotmail.com Two Titans and a Hunter Twitter Two Titans and a Hunter – Facebook Artwork by @Nitedemon Xbox Live: Nitedemon, Peroty, Not Arf & No1RespawnsInRL End credits theme song by Elsewhere - YouTube Channel Plus as always, thank you to Alexander at Orange Free Sounds & www.freesound.org for all the sound effects used in our podcast.  Required Stuff: Bungie - This Week at Bungie March 6th 2025 360GameTV - Old Season Pass Access Daltnix - 0.43 TTK Hunter PvP Build Spade - The Most Terrifying Prismatic PvP Hunter Build Aztecross - Unkillable Titan PvE Build Esoterickk - Solo GM Titan Sword Build Duddits II - Crazy Kinetic Tremors/Elemental Honing Mactics - Best Meta Titan PvE Build Jackeddidge - 27 Free Raid Chest For Solo's Maven - It's Better Than You Think: Titan Build Esoterickk - YouTube Channel Twitch - GuardianDownBot Raid Checkpoints Twitch - IceBreakerCatty. Pluderthabooty Channel Mactics Channel Engram.Blue Link

Back to the Future Part II & III is a platform game based on the movies of the same name. The object of the game is to collect misplaced objects from various time periods like 1955, 1985 and 2015, and bring them back to their proper time period and location. The game often requires the player to solve a small puzzle to figure out what item fits the location he has found. Support NEStalgia directly by becoming a member of our Patreon at https://www.patreon.com/Nestalgia Members at the $5 and above level get access to our brand new show NEStalgia Bytes. A look at the famicom games you can play without any Japanese knowledge! For More NEStalgia, visit www.NEStalgiacast.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BJE865. CME/MOC/AAPA/IPCE credit will be available until November 21, 2025.Resect and Protect Against Melanoma Recurrence: Are You Prepared for the Present and Future of Adjuvant Immunotherapy for Stage II-III Disease? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.

"The doll's trying to kill me and the toaster's been laughin' at me!" Part 6 of our Simpsons deep dive. We watched: S02E03 - Treehouse of Horror S03E06 - Treehouse of Horror II S04E05 - Treehouse of Horror III

Josh and Michael's Spanish Sojourn continues with their review of Day 2 of the European Society of Medical Oncology. Your hosts have been on their feet rushing from lecture theatre to lecture theatre, attending as many incredible presentations and soaking in as much practice-changing information as their brains could manage. In this episode, Michael and Josh report presented data ranging from supportive care to head and neck cancer and so many other fascinating studies in between. Read on to listen to the boys' best bits from Barcelona on Day 2 of ESMO.Studies discussed in this episode:Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor 15, in patients with cancer cachexia: A randomized, placebo-controlled, phase II studyA multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)Final analysis of a phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of the head and neck (JCOG1008)Final results: Randomized assessment of cisplatin dosing interval for ototoxicity (RADIO) trial comparing chemoradiation (CRT) with cisplatin q3weekly to weekly for locally advanced squamous cell carcinoma of the head and neck (LASCCHN)TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trialPathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based studyInterim analysis of GALAXIES Lung-201: belrestotug + dostarlimab in 1L for PD-L1 TPS >/= 50% NSCLCIvonescimab +/- ligufalimab + FOLFOXIRI as 1L treatment for mCRCEfficacy and safety of ribociclib + NSAI in younger patients with HR+/HER2- EBC (NATALEE)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comSpotify Link to Prof Joshua's podcast, Dangerous Ideas in Drug Development: https://podcasters.spotify.com/pod/show/nectaOncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

ADA Compliance Directory now offers free ADA website audits and monthly monitoring and updates. These services can be used by local state governments (ADA Level II) and public businesses (ADA Level III). Learn more at https://www.ada-compliance.com US Enterprises LLC dba ADA Website Compliance City: Marlton Address: 525 Rte 73 N Website: https://www.ada-compliance.ai Phone: +1-856-856-3702 Email: brian@ada-compliance.ai

În 1968 Partidul Comunist Român, sub conducerea lui Nicolae Ceaușescu, a pornit un fals proces împotriva unor abuzuri ale Securității, din perioada în care PCR era condus de Gheorghe Gheorghiu-Dej iar ministru de interne și conducător de facto al Securității era Alexandru Drăghici. De fapt, Ceaușescu a vrut doar să își elimine concurența la conducerea partidului și să își creeze o imagine de reformator politic. În urma acestui proces a apărut falsa distincție între “securitatea rea”, stalinistă (dejistă) și “securitatea bună”, reformată după preluarea puterii în partid de către Nicolae Ceaușescu.Dar Securitatea nu a fost niciodată bună. Abuzurile și teroarea au continuat până în 1989.

paypal.me/LibroTobias Esta semana en nuestra “Sección principal” hago otro especial de series, por si es el último. Os hablo del tercer spin off de The Walking Dead, The Ones Who Live, os hablaré de las seis temporada de House of Cards, las dos temporadas de la serie Wolf Creek que surgió tras el éxito de las dos películas australianas con el mismo título y finalmente, años después de hablar de la primera temporada de True Detective os comento ahora las otras 3 temporadas. Además en nuestra sección “El callejón oscuro” os traigo a John Joseph Joubert IV, un asesino en serie declarado culpable de asesinar a tres niños, uno en Maine y dos en Nebraska y que acechaba a sus víctimas en un coche con el que rondaba por donde residían sus futura víctimas. A causa de la incompetencia de las autoridades locales y a que asesinó en dos estados diferentes, el FBI entro de lleno en su caso. Tiempos: Sección principal: del 00:03:51 al 03:26:33 Sección “El callejón oscuro”: del 03:26:34 al 04:23:52 Presentación, dirección, edición y montaje: Asier Menéndez Marín Diseño logo Podcast: albacanodesigns (Alba Cano) Escucha el episodio completo en la app de iVoox, o descubre todo el catálogo de iVoox Originals

On this week's episode of our show, Captain Ingle and I and our special guest Justin Toner set a course for the 24th AND 32nd centuries and the voyages of both the Enterprise-D and the Discovery. The reason for this is that in addition to the classic two-parter episode "Unification" from The Next Generation, the story was given a sequel of sorts in the form of the Discovery episode "Unification III", wherein the story of the Romulans and Vulcans continues. Join us as we go boldly! --- Send in a voice message: https://podcasters.spotify.com/pod/show/pageturnerstheywerenot/message

Want access to more wisdom in time? Get access to over 1,500 +1's (just like this!) and 650+ Philosopher's Notes (distilling life-changing big ideas from the best self-development books ever written) and a LOT more with our Heroic Premium membership. Learn more and get 30 days free at https://heroic.us

Francis's favorite nephews continue down the literary journey by reading some more of Mario Puzo's Godfather source material; books 2, 3 and 4 of the eponymous novel. Find out just what Johnny Fontaine was up to after Jack Woltz found a horse head in his bedsheets as well as life with Sonny as the Don.

BUFFALO, NY- March 27, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.” In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, Elizabeth A. Mittendorf, and Jennifer K. Litton from the University of Texas MD Anderson Cancer Center, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, and Harvard Medical School conducted a clinical trial to assess the feasibility of enrolling patients with Stage II or III hormone receptor positive (HR+)/HER2-negative breast cancer to pre-operative dual PD-L1/CTLA-4 checkpoint inhibition administered prior to neoadjuvant chemotherapy (NACT). “This feasibility study was conducted to begin testing the hypothesis that dual checkpoint blockade would increase TIL and enhance the response to subsequent NACT in patients with stage II or III HR+/HER2-negative breast cancer.” Eight eligible patients were treated with upfront durvalumab and tremelimumab for two cycles. Patients then received NACT prior to breast surgery. Seven patients had baseline and interval breast ultrasounds after combination immunotherapy and the responses were mixed: 3/7 patients experienced a ≥30% decrease in tumor volume, 3/7 a ≥30% increase, and 1 patient had stable disease. At the time of breast surgery, 1/8 patients had a pathologic complete response (pCR). The trial was stopped early after 3 of 8 patients experienced immunotherapy-related toxicity or suspected disease progression that prompted discontinuation or a delay in the administration of NACT. Two patients experienced grade 3 immune-related adverse events (1 with colitis, 1 with endocrinopathy). Analysis of the tumor microenvironment after combination immunotherapy did not show a significant change in immune cell subsets from baseline. “There was limited benefit for dual checkpoint blockade administered prior to NACT in our study of 8 patients with HR+/HER2-negative breast cancer.” DOI - https://doi.org/10.18632/oncotarget.28567 Correspondence to - Haven R. Garber - hrgarber@mdanderson.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28567 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, breast cancer, ER positive, immunotherapy, neoadjuvant chemotherapy, tumor microenvironment About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes Visit learnAMAstyle.com for free downloads regarding editing and the AMA Manual of Style tip sheet.  Nexletol and Nexlizet for LDL Lowering and CV Risk: The FDA approved bempedoic acid (Nexletol) and its combination with ezetimibe (Nexlizet) for reducing cardiovascular risk and treating primary hyperlipidemia. Bempedoic acid inhibits a cholesterol synthesis enzyme, while ezetimibe blocks cholesterol absorption, both lowering LDL-C levels. The approval, for high-risk patients not yet having cardiovascular events, was based on the CLEAR Outcomes trial. Iclusig for ALL: The FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for treating previously untreated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib, a tyrosine kinase inhibitor, is the first targeted agent for this leukemia type in combination with chemotherapy, based on the PhALLCON trial results. Further confirmatory data may be required to verify its clinical benefit. Elahere for Ovarian Cancer: Mirvetuximab soravtansine-gynx (Elahere) received FDA approval for treating folate receptor alpha-positive, platinum-resistant ovarian cancer, marking it as the first antibody-drug conjugate in the U.S. for this condition. The treatment targets cancer cells by binding to the folate receptor alpha, delivering a cytotoxic agent. Approval was based on the Phase 3 MIRASOL trial. Duvyzat for DMD: The FDA approved givinostat (Duvyzat) for patients 6 years or older with Duchenne muscular dystrophy (DMD), a rare neuromuscular condition. Givinostat is an HDAC inhibitor that mitigates muscle damage and slows disease progression. Approval was based on the EPIDYS trial results, granted to Italfarmaco S.p.A. Spevigo for Psoriasis: Spesolimab-sbzo (Spevigo) received FDA approval for treating generalized pustular psoriasis (GPP) in adults and pediatric patients, expanding its indication from initial approval for GPP flares. As the first targeted therapy for GPP, it acts as an IL-36 receptor antagonist. The expanded approval was based on the Effisayil 2 trial, showing significant reduction in GPP flares. Tryvio for Hypertension: The FDA approved aprocitentan (Tryvio) in combination with other antihypertensive drugs for adults not adequately controlled on other medications, marking it as the first new oral antihypertensive therapy pathway in nearly 40 years. Based on the PRECISION trial, aprocitentan was shown to be effective in patients with resistant hypertension. Opsynvi for PAH: Macitentan and tadalafil (Opsynvi) was approved by the FDA for adults with pulmonary arterial hypertension (PAH) and WHO functional class II-III, as the first once-daily single-tablet combination therapy for PAH. The approval was based on the A DUE study, demonstrating greater reduction in pulmonary vascular resistance compared to monotherapies. Lenmeldy for Juvenile Metachromatic Leukodystrophy: The FDA approved Lenmeldy (atidarsagene autotemcel) gene therapy for children with metachromatic leukodystrophy (MLD), a rare genetic disease affecting the brain and nervous system. The therapy uses the patient's own genetically modified stem cells to produce the missing enzyme. Approval was based on significant improvements in survival, mobility, and cognitive functions observed in clinical trials and an expanded access program.

From music becoming illegal to sexual expression becoming illegal, Joe has quite the dystopian adventure. After plooking Sy Borg too hard, he ends up in jail and is forced to create music in his own mind to save himself from becoming a drone for this new "orderly" society. "The White Zone is for loading and unloading only. If you have load or unload, go to the White Zone. You'll love it." --The Central Scrutinizer Links: Everything you need to know about Joe's Garage: https://www.donlope.net/fz/notes/Joe%27s_Garage.html#Dong OUR DISCORD: https://discord.gg/2stA2P7pTC Flyover State Hotline - 1 608 HIT-NERD (608-448-6373) https://www.youtube.com/flyoverstatepark EVERYTHING ELSE: https://linktr.ee/FlyoverStatePark --- Support this podcast: https://podcasters.spotify.com/pod/show/albumconcepthour/support

Recorded by Brad Walrond for Poem-a-Day, a series produced by the Academy of American Poets. Published on February 2, 2024. www.poets.org

In episode #78 of

Church of Jesus Christ Study Session seeks to generate reflection about areas in the Restored Gospel. Whether it's Come Follow Me, a General Conference talk or a recent Gospel Topic, hopefully you'll find something to keep the Spirit of Christ in your life. Twitter - @mattsroberts90 ldsstudysession@gmail.com You can also join the discussion in the Facebook Group 'Church of Jesus Christ Study Session with Come Follow Me'. You can purchase my book, From Father to Child: Raising a Child to Spiritual Strength in Generation Alpha at the link here: https://www.amazon.co.uk/Father-Child-Spiritual-Strength-Generation-ebook/dp/B08DRLWWZD/ref=mp_s_a_1_3?dchild=1&keywords=from+father+to+child&qid=1596387393&sr=8-3

Join Ben and Collin as they break down all of the Christopher Reeve Superman films. And yes, even the fourth one.

Commentary by Dr. Valentin Fuster

The Crew Meets The Godslayer. As they reunite after the initial breach, the crew is shocked to see the altercation between Xalduin and Oliver. After a brief discussion with Oliver, the crew takes a moment to communicate and reassign targets to the generals after seeing the initial fallout. This will get worse.Support the show

Are the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??

How do you build a massive mountain lobster? How long did we know that some folks were pixelated? And what hot dogs are the best hot dogs? All that and more on the Afterparty!   Here's the Shadow of the Colossus D&D zine, a completo, Crif Dogs, and a Seattle dog.    Sponsors - Hero Forge, where you can now get Color Standees! Visit heroforge.com to start designing your custom miniature today. - Squarespace. Go to squarespace.com/jointheparty for a free trial, and when you're ready to launch, use offer code JOINTHEPARTY to save 10% off your first purchase of a website or domain.  - BetterHelp, a secure online therapy service. Get 10% off your first month at betterhelp.com/jointheparty   Find Us Online - website: jointhepartypod.com - patreon: patreon.com/jointhepartypod - twitter: twitter.com/jointhepartypod - facebook: facebook.com/jointhepartypod - instagram: instagram.com/jointhepartypod - tumblr: jointhepartypod.tumblr.com - merch & music: jointhepartypod.com/merch   Cast & Crew - Dungeon Master, Co-Producer: Eric Silver - Co-Host (Milo Lane), Co-Producer, Editor, Sound Designer, Composer: Brandon Grugle - Co-Host (Aggie O'Hare), Co-Producer: Amanda McLoughlin - Co-Host (Val Vesuvio), Co-Producer, Editor: Julia Schifini - Multitude: multitude.productions   About Us Join the Party is a D&D actual play podcast with tangible worlds, genre-pushing storytelling, and collaborators who make each other laugh each week. We welcome everyone to the table, from longtime players to folks who've never touched a roleplaying game before. Begin with Campaign 2 (The Join Campaign) for a modern, sci-fi superhero game, or marathon all of Campaign 1 (The Party Campaign) for a high fantasy story. And once a month we release the Afterparty, where we answer your questions about the show and how we play the game. New episodes every Tuesday.